Persistence of anti-HBs titers after two different doses of Genevac B, a recombinant hepatitis B vaccine, in healthy adolescents [4]

Indian Journal of Gastroenterology

Volumn 26, Issue 1, 2007, Pages 48-

  Velu, Vijayakumar ^a   Nandakumar, Subhadra ^a   Shanmugam, Saravanan ^a   Thyagarajan, Sadras Panchatcharam ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GENEVAC B; HEPATITIS B SURFACE ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADOLESCENT HEALTH; ADULT; ANTIBODY TITER; BLOOD SAMPLING; CONTROLLED STUDY; DRUG COST; DRUG DOSE COMPARISON; FEMALE; FEVER; HEPATITIS B; HUMAN; IMMUNOGENICITY; LETTER; MAJOR CLINICAL STUDY; MALE; SEROCONVERSION;

ADOLESCENT; ADULT; CHILD; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MALE;

EID: 34248160393     PISSN: 02548860     EISSN: 02548860     Source Type: Journal    
DOI: None     Document Type: Letter

References (1)

1. Kulkarni PS, Raul SK, Patki PS, Phadke MA, Jadhav SS, Kape SV, et al. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults. Vaccine 2006;24:3457-60.